Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24867506 | 0.81 | MAPK14 (0.50) | PTGDR2HDAC6MAPK1MAPK14GSK3A | |
| SCHEMBL30572264 | 0.78 | ALDH1A1 (0.47) | MAPK1GSK3AGSK3B | |
| SCHEMBL30572279 | 0.78 | GSK3B (0.45) | CLK2CLK3DYRK1AGSK3AGSK3B | |
| SCHEMBL13322178 | 0.77 | GSK3B (0.43) | MAPK1GSK3AGSK3B | |
| SCHEMBL25224747 | 0.76 | FNTA (0.48) | POLBMAPK14MAPK11 | |
| SCHEMBL25222404 | 0.76 | MAPK1 (0.53) | MAPK1 | |
| SCHEMBL25213716 | 0.76 | GSK3B (0.42) | MAPK1MAPK14GSK3AGSK3B | |
| SCHEMBL25244400 | 0.76 | FNTA (0.38) | MAPK1MAPK14MAPK11 | |
| SCHEMBL24867045 | 0.75 | NTRK1 (0.44) | MAPK1MAPK14GSK3AGSK3B | |
| SCHEMBL25214548 | 0.75 | GSK3B (0.44) | MAPK1POLBMAPK14GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008433-A1 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008433-A1 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | PTGDR2 4517/4885HDAC6 534/4885MAPK1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.